Smell disorders affect an estimated 22 percent of the population, yet the conditions have been poorly understood, chronically underdiagnosed, and routinely minimized by the doctors who are supposed to treat them. That gap between prevalence and clinical attention is not a minor oversight — it is a structural failure in how medicine has categorized and prioritized sensory health. The story of Chrissi Kelly illustrates just how costly that failure can be.

A Common Condition That Medicine Has Long Dismissed

Kelly lost her sense of smell approximately 14 years ago after contracting a virus during a visit to family in the Czech Republic. When the loss persisted for months, she sought answers from her general practitioner and an ear, nose and throat specialist. The diagnosis she received — anosmia, or complete smell loss — came packaged with a prognosis that has become standard for patients with her condition: learn to live with it.

That response is worth examining. Anosmia is not an obscure edge case. Researchers estimate that up to 22 percent of the population lives with some form of smell impairment, a category that includes hyposmia, or partial smell loss, alongside anosmia. Beyond that, smell disorders extend further into parosmia — where previously pleasant smells like coffee or shampoo are perceived as deeply unpleasant, often described as resembling feces or vomit — and phantosmia, where a person detects smells that are not present at all.

The Human Cost of Being Told to Cope

Kelly's account makes clear what clinicians tend to underweight. After roughly six months of complete loss, she described feeling as though she were climbing the walls and no longer recognizing herself. That is not a trivial quality-of-life complaint. Smell is tightly bound to memory, appetite, pleasure, and the basic experience of being present in the world. Stripping it away without treatment or follow-up is not a neutral outcome.

What Underdiagnosis Actually Means at Scale

The clinical tendency to minimize smell disorders has downstream consequences that compound over time. When conditions go undiagnosed, they go uncounted. When they go uncounted, research funding and treatment development lag. When treatment development lags, the next patient who sits across from a GP or ENT specialist receives the same dismissal Kelly did — years later, nothing changed.

The 22 percent estimate alone should have been enough to force a reappraisal of how smell impairments are screened and coded in routine care. That it has not is less a mystery than a choice — one the medical establishment has made, largely by default, for a very long time.